Valneva – About the Company

Valneva SE (NYSE Euronext: VLA.PA) is a French biotechnology company that markets and develops vaccines for infections and diseases that pose serious threats to public health. The Company’s commercialized vaccines include IXIARO to protect against Japanese encephalitis and DUKORAL for cholera and some forms of diarrhea caused by ETEC. These products generated a combined global revenue of €53.7 million ($71.4 million) in 2014. In addition, the Company is developing prophylactic vaccine candidates against Pseudomonas aeruginosa and Clostridium difficile for use in at-risk patient populations. Valneva has completed enrollment of a pivotal Phase II/III trial evaluating its P. aeruginosa vaccine candidate, and results are expected in the second quarter of 2016. The Company is also recently announced strong immunogenicity data from a Phase II trial for its C. difficile vaccine.